53786-10-0

Usage

Chemical Properties

Yellowish solid

InChI:InChI=1/C13H17N3O/c1-15-11-4-2-3-5-12(11)16(13(15)17)10-6-8-14-9-7-10/h2-5,10,14H,6-9H2,1H3

Upstream product

• 79099-00-6 tert‐butyl 4‐((2‐aminophenyl)amino)piperidine‐1‐carboxylate 
• 87120-73-8 tert‐butyl 4‐((2‐nitrophenyl)amino)piperidine‐1‐carboxylate 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 173843-48-6 4-(3-Methyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylicacid tert-butyl ester 
• 20662-53-7 4-(2-keto-1-benzimidazolinyl)piperidine 
• 87120-81-8 1,3-dihydro-1-(1-tert-butyloxycarbonylpiperidin-4-yl)-2H-benzimidazol-2-one 
• 1493-27-2 ortho-nitrofluorobenzene 
• 87120-77-2 ethyl 4-((2-aminophenyl)amino)piperidine-1-carboxylate 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 53786-47-3 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-piperidine-1-carboxylic acid ethyl ester 
• 85443-52-3 ethyl 4-((2-nitrophenyl)amino)piperidine-1-carboxylate 
• 74-88-4 methyl iodide 

Downstream Products

• 400801-21-0 1-{3-[4-(3-Methyl-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3-(4-trifluoromethyl-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester 
• 400797-44-6 (S)-1-(1-{2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperidin-4-yl)-3-methyl-1,3-dihydro-benzoimidazol-2-one 
• 74406-07-8 1-[2-(3,4-dihydroxyphenyl)-2-hydroxy]ethyl-4-(3-methyl-2-oxobenzimidazolin-1-yl)piperidine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

Effects of Pimozide Derivatives on pSTAT5 in K562 Cells

STAT5 is a transcription factor, a member of the STAT family of signaling proteins. STAT5 is involved in many types of cancer, including chronic myelogenous leukemia (CML), in which this protein is found constitutively activated as a consequence of BCR-ABL expression. The neuroleptic drug pimozide was recently reported to act as an inhibitor of STAT5 phosphorylation and is capable of inducing apoptosis in CML cells in vitro. Our research group has synthesized simple derivatives of pimozide with cytotoxic activity and that are able to decrease the levels of phosphorylated STAT5. In this work we continued the search for novel STAT5 inhibitors, synthesizing compounds in which the benzoimidazolinone ring of pimozide is either maintained or modified, in order to obtain further structure–activity relationship information for this class of STAT5 inhibitors. Two compounds of the series showed potent cytotoxic activity against BCR-ABL-positive and pSTAT5-overexpressing K562 cells and were able to markedly decrease the levels of phosphorylated STAT5.

Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors

A novel series of competitive, reversible cathepsin S (CatS) inhibitors was discovered and optimized. The 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety was found to be an effective replacement for the 4-arylpiperazin-1-yl group found in our earlier series of CatS inhibitors. This replacement imparted improved PK properties as well as decreased off-target activity. Optimization of the ketobenzimidazole moiety led to the discovery of the lead compound JNJ 10329670, which represents a novel class of selective, noncovalent, reversible, and orally bioavailable inhibitors of cathepsin S.

Method for treating allergies using substituted pyrazoles

A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.